Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients
Brief Summary: Changes in chelation treatment and transfusion practices, during the past two decades, have dramatically improved the prognosis of thalassemia major patients.Deferiprone (DFP) has been compared with deferoxamine (DFO), using different schedules of treatment, in the majority of the 13 clinical trials published between 1990 and 2008.No statistically significant difference was shown between these two interventions during, at most, 18 months of treatment.Three randomised trials that compared sequential DFP-DFO treatment versus DFO alone reported controversial results but this could be due to small sample sizes and short treatment duration. In fact, no trial with treatment duration longer than 18 months15, which reported on mortality, adverse events, serum ferritin concentrations, as well as costs has so far been published.

This long-term sequential DFP-DFO treatment versus DFP alone treatment trial was conducted to assess the impacts of these chelation treatments on serum ferritin concentrations, mortality, adverse events, and costs in thalassemia major patients.


Options:
A: Arm Label: Thalassemia cohort; Type: N/A; Interventions: N/A | Arm Label: Successful SCT cohort; Type: N/A; Interventions: N/A
B: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
C: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Core Study: Deferasirox, Drug: Deferasirox | Arm Label: Deferasirox Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Core Study: Deferoxamine, Drug: Deferoxamine | Arm Label: Extension: deferoxamine to deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferoxamine to deferasirox | Arm Label: Extension: deferasirox to deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Core Study: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Core Study: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo | Intervention Type: DRUG; Name: Extension: deferoxamine to deferasirox; Assigned to Arm(s): Extension: deferoxamine to deferasirox | Intervention Type: DRUG; Name: Extension: deferasirox to deferoxamine; Assigned to Arm(s): Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2

Answer: D